Abstract:OBJECTIVES:With the decreased protective effect of Bacille Calmette-Guérin (BCG) vaccine, widespread drug-resistant strains of tuberculosis as well as the lack of effective vaccines, global morbidity and mortality of tuberculosis remains high. The purpose of this study is to evaluate the potential of Mycobacterium tuberculosis antigen Rv2654 as a candidate vaccine against tuberculosis, and to verify the characteristics of cellular and humoral immune responses in mice induced by this protein.METHODS:Isopropyl-beta-D-thiogalactoside (IPTG) was added to induce the expression of Rv2654 recombinant protein in the logarithmic growth stage of bacteria. The recombinant protein was purified by affinity chromatography and identified by Western blotting. The immunoreactivity of Rv2654 recombinant protein with human sera was detected by ELISA. After immunization with Rv2654 recombinant protein, the levels of Th1/Th2 cytokines in peripheral blood of mice was measured using cytokine magnetic bead arrays, and the T and B lymphocyte subsets in spleen of mice was analyzed by flow cytometry.RESULTS:The recombinant protein Rv2654 was successfully induced and expressed. The ELISA data showed that the recombinant protein Rv2654 was responsive to the serum of BCG-inoculated patients or active pulmonary tuberculosis patients. In immunized mice with recombinant protein Rv2654, the expression of IFN-γ, TNF-α, IL-2, IL-4, IL-6, IL-10 and other cytokines in peripheral blood was elevated (all P<0.05). Flow cytometry analysis showed that the recombinant protein significantly stimulated the differentiation of CD4+T cells and CD8+T cells into effector T cells, and this effect was more obvious when combined with BCG. The recombinant protein Rv2654 also stimulated the activation and proliferation of B cells and their differentiation into memory cells. However, less plasma cells were produced.CONCLUSIONS:Rv2654 protein could induce the cell immune responses and it has good binding ability with serum of BCG-inoculated patients and active pulmonary tuberculosis patients, suggesting that it may serve as a good candidate antigen for tuberculosis immunological prophylaxis and diagnostic vaccines.

Protective and therapeutic efficacy of Mycobacterium smegmatis expressing HBHA-hIL12 fusion protein against Mycobacterium tuberculosis in mice.

Immune Responses and Protection Induced by a Recombinant Mycobacterium smegmatis Expressing an HBHA and hIL-12 Fusion Protein Against M.tuberculosis Infection

Therapeutic Efficacy of a Recombinant Mycobacterium Smegmatis Expressing Anhbha and Hil12 Fusion Protein Against Mycobacterium Tuberculosis Infection Induced in Mice

Gls/Il-12-Modified Mycobacterium Smegmatis As A Novel Anti-Tuberculosis Immunotherapeutic Vaccine

Recombinant M. Smegmatis Vaccine Targeted Delivering IL-12/GLS into Macrophages Can Induce Specific Cellular Immunity Against M. Tuberculosis in BALB/c Mice

Immunotherapeutic Efficacy of Recombinantmycobacterium Smegmatisexpressing Ag85B–ESAT6 Fusion Protein Against Persistent Tuberculosis Infection in Mice

Immunogenicity and Protective Efficacy of a Fusion Protein Vaccine Consisting of Antigen Ag85B and HspX Against Mycobacterium Tuberculosis Infection in Mice

Construction and Identification of Recombinant Mycobacterium Smegmatis Which Expressing Fusion Gene of Heparin-Binding Haemagglutinin and Human IL12

The Evaluation of Recombinant HBHA Vaccine by Mice Model Infected with Mycobacterium Tuberculosis

Immunomodulatory Effects of Recombinant Mycobacterium smegmatis Expressing Antigen-85B Epitopes in Infected J774A.1 Murine Macrophages

Evaluation Of A New Recombinant Bcg Which Contains Mycobacterial Antigen Ag85b-Mpt64(190-198)-Mtb8.4 In C57/Bl6 Mice

Immunogenicity of the Recombinant M.smegmatis Expressing Ag85B-ESAT-6 Fusion Protein of M.tuberculosis in Mice

The Development and Preliminary Evaluation of a Newmycobacterium Tuberculosisvaccine Comprising Ag85b, HspX and CFP-10:ESAT-6 Fusion Protein with CpG DNA and Aluminum Hydroxide Adjuvants

Subunit Vaccine Consisting Of Multi-Stage Antigens Has High Protective Efficacy Against Mycobacterium Tuberculosis Infection In Mice

Evaluation of Immunotherapy Efficacy of M. Smegmatis and Vaccae in Murine Model of M. Tuberculosis Infection

Recombinant Bcg Coexpressing Ag85b, Esat-6 and Mouse-Ifn-Gamma Confers Effective Protection Against Mycobacterium Tuberculosis in C57bl/6 Mice

Expression and Purification of Rv2654 Recombinant Protein from Mycobacterium Tuberculosis and Its Characteristics of Immune Response.

Immune responses and protective efficacy induced in mice by Mycobacterium tuberculosis MPT64-ESAT6 fusion protein

The effect of immunization by recombinant Mycobacterium smegmatis encoding GLS and IL-12 in mice

Recombinant Bcg Coexpressing Ag85b, Esat-6 and Rv3620c Elicits Specific Th1 Immune Responses in C57bl/6 Mice

Immune response and protective efficacy induced by fusion protein ESAT6-CFP10 of M.tuberculosis in mice]